newsfilter
← Latest News
Business Wire·

Amylyx Pharmaceuticals Announces $350.0 Million Proposed Public Offering of Common Stock

  • Amylyx Pharmaceuticals commenced an underwritten public offering of $350.0 million in common stock shares.
  • The company intends to grant underwriters a 30-day option to purchase up to an additional $52.5 million in shares.
  • Net proceeds will fund pre-commercial activities for avexitide, research & development, & general corporate purposes.
  • Leerink Partners, Morgan Stanley, Guggenheim Securities, & LifeSci Capital are acting as joint bookrunning managers.
  • The offering is conducted under a shelf registration statement on Form S-3ASR effective March 3, 2026.
  • Actual completion & terms of the offering remain subject to market conditions & other risks.